Objective-Serum levels of fibroblast growth factor-21 (FGF21), a metabolic hormone, have been shown to be elevated in subjects with adverse lipid profiles, obesity, metabolic syndrome, impaired glucose tolerance, type 2 diabetes mellitus, and hypertension. Recently, elevated serum FGF21 levels have also been reported in subjects with coronary heart disease or carotid artery plaques. However, whether serum FGF21 is independently associated with atherosclerotic diseases remains unclear. In this study, we examined the relationship between serum FGF21 levels and carotid intima-media thickness (IMT) in a large cohort of Southern Chinese subjects. Approach and Results-The cohort consisted of 670 subjects who underwent carotid IMT measurement. Serum FGF21 levels were measured with an ELISA kit. Serum FGF21 levels positively correlated with carotid IMT in women (r=0.32; P<0.001), but not in men (r=0.06; P=0.305). On multiple linear regression analysis, elevated serum FGF21 level in women was an independent risk factor for increased carotid IMT (P=0.039), together with age (P<0.001) and hypertension (P=0.011), in a model comprising also waist circumference, smoking history, serum creatinine, high sensitive C-reactive protein, dysglycemia, and dyslipidemia (adjusted R 2 =35.8%; P<0.001). Elevated serum FGF21 levels were also a significant independent risk factor of carotid IMT on multiple stepwise regression analysis (P=0.01).
T he family of fibroblast growth factors (FGFs) has a wide range of biological functions. Among members of the endocrine subfamily, FGF19 and FGF21 possess distinct regulatory roles in glucose and lipid homeostasis, whereas FGF23 is an important regulator of phosphate and vitamin D metabolism. 1, 2 The role of FGF21 in glucose and lipid metabolism has been extensively studied recently. Human recombinant FGF21 has been demonstrated to stimulate glucose incorporation in mouse and human adipocytes, and lower blood glucose and triglyceride levels when administered to diabetic and obese mice, 3 and diabetic monkeys. 4 In contrast, FGF21-deficient mice had mild weight gain and slightly impaired glucose homeostasis and also developed hepatosteatosis and marked impairments in ketogenesis and glucose control when fed on ketogenic diet. 5 Collectively, these findings suggest that FGF21 is a metabolic hormone that plays a significant role in glucose and lipid homeostasis.
However, despite the demonstrated beneficial metabolic effects in animals, serum FGF21 levels have been shown to be elevated in humans with adverse lipid profiles, obesity, metabolic syndrome, impaired glucose tolerance, type 2 diabetes mellitus (DM), and hypertension. [6] [7] [8] [9] [10] This has led to the postulation that these subjects may have FGF21 resistance, analogues to the finding of insulin resistance in these clinical conditions. In agreement with this hypothesis, the presence of FGF21 resistance in obesity has been demonstrated in an animal study, where the administration of exogenous FGF21 to obese mice has resulted in less reduction in levels of circulating glucose and nonesterified fatty acids, compared with the responses in the lean littermates. 11 Apart from its correlations with various adverse metabolic parameters, elevated serum FGF21 levels have recently been reported in subjects with coronary heart disease (CHD) and are associated with the presence of carotid artery plaques in subjects with type 2 DM. 12, 13 However, whether serum FGF21 is independently associated with atherosclerotic diseases remains unclear. To evaluate the relationship between serum FGF21 levels and atherosclerosis, we examined in 670 Southern Chinese subjects with no overt macrovascular disease the association between serum FGF21 levels and carotid intima-media thickness (IMT), a well-established marker of atherosclerosis. 14 Established cardiovascular risk factors and high sensitive C-reactive protein (CRP) were also measured to determine whether FGF21 is an independent risk factor for increased carotid IMT.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
The demographic and biochemical characteristics of the subjects are summarized in Table 1 . Of the 502 subjects recruited from the third assessment of the Hong Kong Cardiovascular Risk Factor Prevalence Study, 262, 128, and 112 had normal glucose tolerance, impaired glucose tolerance (IGT)/impaired fasting glucose (IFG) and DM, respectively. In all, 176 (26.3%) and 76 (11.3%) of the 670 subjects were on antidiabetic and lipid-lowering medications, respectively. The former group comprised 109 metformin-treated subjects. For the use of peroxisome proliferator-activated receptors agonists, 20 subjects of the entire cohort were treated with fibrates and none of them was on thiazolidinediones. For these treatment modalities, there were no between-group differences in serum FGF21 levels based on analysis in which subjects were stratified according to the use of medication.
Among subjects with different glycemic status, DM and IGT/IFG subgroups had significantly higher serum FGF21 levels compared with normal glucose tolerance: 288.4 (172.9-450.0) ng/L and 293.4 (170.7-445.8) ng/L versus 191.1 (125.6-329.7) ng/L, respectively (P<0.001). There was no significant difference between DM and IGT/IFG subgroups. Thus, for all subsequent analyses on the relationship between glycemic status and IMT, the IGT/IFG and DM subjects were combined and labeled as the group with dysglycemia.
Men had significantly thicker carotid IMT: 0.73±0.17 versus 0.65±0.14 mm in women (P<0.001), and higher prevalence of plaque: 35.8% versus 21.8% (P<0.001), but similar FGF21 levels (P=0.309; Table 1 ) compared with women. For the established cardiovascular risk factors, men were older, had higher waist circumference (WC), diastolic blood pressure, serum triglycerides (TG) and creatinine levels, and lower high-density lipoprotein-cholesterol level, compared with women (all P<0.001 except for age, P=0.034, and TG, P=0.012). In addition, men were more likely to be current or past smokers (52.6% versus 7.0% in women; P<0.001) and dysglycemic (67.0% versus 56.4%, P=0.005; Table 1 ). In Data presented as mean±SD or median (interquartile range); central obesity was defined as waist circumference >90 cm for men, >80 cm for women. CRP indicates C-reactive protein; DBP, diastolic blood pressure; FGF21, fibroblast growth factor-21; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HT, hypertension; IMT, intima-medial thickness; LDL, low-density lipoprotein; and SBP, systolic blood pressure.
*Adjusted SBP, DBP. †Log-transformed before analysis.
the entire cohort, men or women subgroup analyses, serum FGF21 levels were significantly higher in subjects with dysglycemia, hypertension, or dyslipidemia ( Table 2) . In all subjects, serum FGF21 levels correlated positively with age, body mass index, WC, fasting glucose, hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, TG, serum creatinine, and CRP, but inversely with high-density lipoprotein-cholesterol (all P<0.001, except for WC, P=0.035; fasting glucose, P=0.012; and hemoglobin A1c, P=0.006; Table I in the online-only Data Supplement).
In women, serum FGF21 levels, age, WC, systolic blood pressure, low-density lipoprotein-cholesterol, TG, serum creatinine, CRP, smoking history, and presence of dysglycemia, hypertension, and dyslipidemia showed significant correlations with carotid IMT in univariate analysis (Tables 3 and 4 ; Figure [ A]). However, in men, age, systolic blood pressure, TG, CRP, smoking history, and presence of hypertension, but not serum FGF21 levels, were significantly associated with carotid IMT (Tables 3 and 4 
; Figure [B]).
On multiple linear regression analysis, sex-adjusted carotid IMT was significantly associated with serum FGF21 levels in the stepwise regression model, but not in the full regression model in which all relevant confounding variables were entered ( Table  II in the online-only Data Supplement; P=0.036 and 0.106). In sex-specific analysis, elevated serum FGF21 level in women was an independent risk factor for increased carotid IMT in the stepwise regression model (P=0.01; adjusted R 2 =36.4%) and also in the full regression model (P=0.039; adjusted R 2 =35.8%), which comprised age (P<0.001), hypertension (P=0.011), WC, smoking history, serum creatinine, CRP, dysglycemia, and dyslipidemia (Table 5 ). However, in men, age, but not FGF21, was independently associated with carotid IMT in both the full and the stepwise regression models (both P<0.001; Table 5 ). Of note, serum FGF21 levels showed a stronger correlation with Framingham risk scores, 15 a tool for predicting the 10-year CHD risk, in women than in men or the entire cohort (r=0.465, P<0.001; r=0.181, P=0.002; and r=0.37, P<0.001).
Discussion
The association of elevated serum FGF21 levels with various established cardiovascular risk factors has been well reported. [6] [7] [8] [9] [10] However, previous studies on the relationship between FGF21 and atherosclerotic diseases in humans have shown conflicting findings. 12, 13, 16 In a study on the correlation of FGF21 and lipid profiles in 135 subjects with CHD, Lin et al 12 reported significantly higher serum FGF21 levels, compared with 61 controls, and their FGF21 levels were associated with adverse lipid profiles. An et al 13 also found, in a subgroup analysis of 141 DM subjects, that the presence of carotid artery plaque was associated with an elevation in serum FGF21 levels. In contrast, another study, which compared 60 CHD subjects with 129 body mass index-matched controls, demonstrated that serum FGF21 levels were not correlated with CHD, despite its significant associations with various established cardiovascular risk factors, such as lipid profiles, insulin resistance, and the metabolic syndrome. 16 The present study, on the basis of a much larger cohort than the previous studies, is the first demonstration that elevated serum FGF21 levels are associated with carotid atherosclerosis in humans, independent of established risk factors, including adverse lipid profiles and CRP.
The observed elevation in serum FGF21 levels in subjects with dysglycemia, hypertension, and dyslipidemia may be a reflection of the underlying FGF21 resistance, analogues to the finding of insulin resistance in these clinical conditions. Indeed, evidence of FGF21 resistance has been demonstrated in obese mice. 11 There is also experimental data suggesting that adipose tissue inflammation in obesity, involving the c-Jun NH 2 -terminal kinase 1 pathway, could result in the suppression of β-Klotho expression by tumor necrosis factors-α and hence impaired FGF21 action in adipocytes. 17 In obese subjects, both serum FGF21 levels and visceral fat FGF21 mRNA expression were significantly higher compared with that of lean subjects. 9 Of note, our study cohort was overweighed with a mean body mass index of almost 25 kg/m 2 and a high central obesity prevalence of 43.9%, which may have contributed to the development of FGF21 resistance. Peroxisome proliferator-activated receptor agonists are known to increase serum FGF21 levels in animals and humans 2, 18 ; however, in our cohort, the number of subjects on such medications was too small for a meaningful conclusion to be drawn.
In fact, FGF21 resistance may occur well before the clinical manifestation of a disease entity, as we have previously shown in a population-based prospective study that elevated serum FGF21 level could independently predict the development of type 2 DM. 19 Hence, it might be speculated that the underlying FGF21 resistance could have led to the development of various cardiovascular risk factors, such as dysglycemia and dyslipidemia, which in turn promoted atherosclerosis. Indeed, the association of elevated serum FGF21 levels with carotid IMT was attenuated, although still significant, after adjustment for the established cardiovascular risk factors. Nonetheless, the observation that elevated serum FGF21 levels remained significantly associated with carotid IMT after adjusting for the established cardiovascular factors would suggest that other mechanisms might be at play. One possibility is that the elevation of serum FGF21 levels in subjects with atherosclerosis may represent a bodily response to the atherosclerotic process. In cultured rodent cardiac microvascular endothelial cells, both FGF21 mRNA and protein expression were upregulated when these cells were incubated with oxidized low-density lipoprotein, a pathogenic factor that promotes atherosclerosis. 20 Hence, it was suggested that FGF21 could be secreted by endothelial cells in response to stress, and its elevated levels may be a signal of endothelial cell injury. Consistent with this observation, elevated serum FGF21 levels have also been demonstrated in mice after the administration of a variety of stimulants that induce an acute phase response. 21 On the basis of these observations, the elevation in serum FGF21 levels in subjects with carotid atherosclerosis may be part of a protective response to the vascular injury or inflammation in atherosclerosis, similar to the increased pancreatic FGF21 expression in ceruleininduced pancreatitis. 22 CRP, as one of the acute phase proteins and the most extensively studied inflammatory biomarker in the literature, has been shown to be associated with features of the metabolic syndrome and carotid IMT and predict cardiovascular mortality in epidemiological studies. [23] [24] [25] [26] A recent study of 69 newly diagnosed DM subjects demonstrated a positive correlation between serum FGF21 levels and CRP. 27 Similarly, serum FGF21 levels also correlated with CRP in the present study. However, elevated serum FGF21 levels remained significantly associated with increased carotid IMT, even after adjustment for CRP, suggesting that serum FGF21 may be another biomarker of atherosclerotic diseases that warrant further investigation.
Study Limitations
The major limitation of this study was its cross-sectional design, which precluded the determination of a causal relationship. Moreover, our findings could not rule out the possibility of a reverse causal relationship between FGF21 and carotid IMT. To address this question, analysis of the association between carotid IMT and single-nucleotide polymorphisms at genetic loci encoding FGF21 and its signaling pathway, 28 or long-term interventional studies involving therapeutic agents such as human recombinant FGF21 or agonistic anti-FGF receptor 1 antibodies, is warranted. In addition, our cohort consists of an over-representation of subjects with dysglycemia, with 41.8% and 19.1% of the subjects having diabetes mellitus and IGT/IFG, respectively. Hence, our findings may not be applicable to the general population, which has a lower prevalence of diabetes mellitus and prediabetes mellitus. Furthermore, this study only demonstrated the association between FGF21 and carotid IMT in women, but not in men. This may be attributed to the overwhelming presence of other cardiovascular risk factors in the male subjects of our cohort, including a higher prevalence of smoking history and an older mean age. The higher propensity to atherosclerotic diseases was actually translated into clinical manifestation, as evidenced by the thicker carotid IMT and higher prevalence of carotid plaques in our male subjects. Our finding of the sex-specific association between serum FGF21 and carotid atherosclerosis remains to be confirmed in other populationbased studies involving an even larger sample size and a wider age range.
Conclusions
Our study is the first demonstration that elevated serum FGF21 levels are associated with carotid atherosclerosis in humans, independent of established risk factors. The role of FGF21 as a biomarker or therapeutic target of atherosclerotic diseases warrants further investigation. 
